How Sotyktu Works Against Psoriasis
Sotyktu (deucravacitinib) is an oral tablet approved by the FDA for adults with moderate to severe plaque psoriasis. It targets a specific immune pathway driving skin inflammation.[1]
It inhibits tyrosine kinase 2 (TYK2), an enzyme in the interleukin-23 (IL-23) signaling pathway. TYK2 activates immune cells like T cells and keratinocytes, leading to overproduction of inflammatory cytokines such as IL-23, IL-12, and type I interferons. By allosterically binding TYK2—locking it in an inactive state—Sotyktu blocks this cascade, reducing plaque formation, scaling, and redness.[2][3]
Unlike JAK inhibitors (which broadly hit JAK1/2/3), Sotyktu's selectivity for TYK2 minimizes off-target effects on other cytokines, potentially lowering risks like infections or blood clots seen with broader JAK drugs.[4]
Clinical Trial Results on Effectiveness
In two phase 3 trials (POETYK PSO-1 and PSO-2), 58-69% of patients on 6 mg daily achieved at least 75% skin clearance (PASI 75) by week 16, compared to 13-22% on placebo. About 36-40% hit near-complete clearance (PASI 90). Benefits persisted through 52 weeks, with response rates holding at 68-75% for PASI 75.[1][5]
Real-world data shows sustained results beyond a year, with many patients maintaining clear or almost clear skin.[6]
How Long Until It Starts Working
Improvement often begins within 4 weeks, with peak effects around 12-16 weeks. Full benefits may take up to 6 months; doctors assess response at 3-4 months before switching.[1][7]
Common Side Effects and Risks
Upper respiratory infections (20%), acne (7%), and folliculitis (5%) occur most often. Serious risks include infections (herpes zoster), malignancies, and major cardiovascular events—similar to other systemic psoriasis treatments. Avoid in active infections or with live vaccines; monitor liver enzymes and lipids.[1][8]
Pregnancy risks are unknown (category not assigned); use contraception during treatment and for 4 weeks after.[7]
How Sotyktu Compares to Other Psoriasis Drugs
| Treatment | Mechanism | Dosing | PASI 75 at 16 Weeks | Key Differences |
|-----------|-----------|--------|---------------------|-----------------|
| Sotyktu | TYK2 inhibitor (oral) | 6 mg daily | 58-69% | First oral targeted therapy; no injections |
| Otezla (apremilast) | PDE4 inhibitor (oral) | 30 mg twice daily | ~30% | Less effective; more GI side effects |
| Skyrizi (risankizumab) | IL-23 inhibitor (injection) | 150 mg at 0/4/every 12 weeks | 75-80% | Higher efficacy; subcutaneous shots |
| Methotrexate | Immunosuppressant (oral/injectable) | Weekly | 30-40% | Cheaper generic; more monitoring for liver toxicity |
| Humira (adalimumab) | TNF inhibitor (injection) | Every 2 weeks | 70-80% | Biosimilars available; higher infection risk |
Sotyktu offers convenience over injectables but trails IL-17/IL-23 biologics in top-line efficacy for some patients.[4][9]
Who Makes Sotyktu and Access Details
Bristol Myers Squibb manufactures and markets it. List price is about $5,600/month before insurance; patient assistance programs cover copays for eligible users.[10]
Patent protection runs through at least 2033 in the US, delaying generics.[11] No biosimilars yet, as it's a small molecule.
Sources
[1]: FDA Label for Sotyktu
[2]: Nature Reviews Drug Discovery on TYK2
[3]: New England Journal of Medicine trial
[4]: JAMA Dermatology comparison
[5]: POETYK PSO-2 results
[6]: One-year extension data
[7]: Sotyktu HCP site
[8]: Postmarketing safety
[9]: Head-to-head reviews
[10]: BMS pricing
[11]: DrugPatentWatch on Sotyktu